 |
138 Diseases |  |
93 Trials |
|
93 Trials |  |
2194 News |  |
| «12...22232425262728293031323334» |
- |||||||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P3 trial: A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids (clinicaltrials.gov) - Jan 14, 2016
P3, N=288, Not yet recruiting, Sponsor: Takeda
- docetaxel / Generic mfg.
Enrollment change, Trial initiation date, Trial primary completion date, Metastases: Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer (clinicaltrials.gov) - Dec 29, 2015
P1, N=20, Active, not recruiting, Sponsor: David T. Marshall
N=36 --> 20 | Initiation date: Jul 2004 --> Jul 2010 | Trial primary completion date: Dec 2012 --> Jan 2011
- Orgalutran (ganirelix acetate) / Organon
Trial completion: Follicle-Stimulating Hormone (FSH) and the Onset of Puberty (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=11, Completed, Sponsor: University of Utah
N=36 --> 20 | Initiation date: Jul 2004 --> Jul 2010 | Trial primary completion date: Dec 2012 --> Jan 2011 Suspended --> Completed
- | Ibrance (palbociclib) / Pfizer
New P2 trial, Combination therapy, Metastases: Young-PEARL: A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC (clinicaltrials.gov) - Oct 30, 2015
P2, N=122, Not yet recruiting, Sponsor: Samsung Medical Center
- Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment open: Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer (clinicaltrials.gov) - Oct 29, 2015
P2, N=53, Recruiting, Sponsor: University of California, San Francisco
Suspended --> Completed Not yet recruiting --> Recruiting
- || anastrozole/levonorgestrel (BAY 98-7196) / Bayer
Trial primary completion date: Bay98-7196, Dose Finding / POC Study (clinicaltrials.gov) - Oct 22, 2015
P2b, N=318, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Trial primary completion date: May 2016 --> Sep 2016
- Yervoy (ipilimumab) / BMS
Trial primary completion date: Ipilimumab + Androgen Depravation Therapy in Prostate Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=48, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: May 2016 --> Sep 2016 Trial primary completion date: Jun 2016 --> Jun 2017
- Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment open: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=56, Recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Jun 2016 --> Jun 2017 Not yet recruiting --> Recruiting
- | Yervoy (ipilimumab) / BMS
Trial completion, Trial primary completion date, IO biomarker: Neoadjuvant Ipilimumab in Prostate Cancer (clinicaltrials.gov) - Oct 15, 2015
P2a, N=19, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Oct 2015
- Livial (tibolone) / Organon
Trial initiation date: Psychological Impact of Amenorrhea in Women With Endometriosis (clinicaltrials.gov) - Sep 22, 2015
P4, N=50, Not yet recruiting, Sponsor: University of Cagliari
Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Oct 2015 Initiation date: Apr 2015 --> Oct 2015
- || sunitinib / Generic mfg.
Trial primary completion date: Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy (clinicaltrials.gov) - Sep 16, 2015
P2, N=64, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Apr 2015 --> Oct 2015 Trial primary completion date: Dec 2015 --> Dec 2017
- | cabazitaxel / Generic mfg.
New P2 trial: ACDC-RP: Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) (clinicaltrials.gov) - Sep 8, 2015
P2, N=74, Not yet recruiting, Sponsor: University Health Network, Toronto
- |||||| Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
Enrollment open, Trial initiation date, Trial primary completion date: Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) - Sep 2, 2015
P3, N=270, Recruiting, Sponsor: Prof. W. Janni
Trial primary completion date: Dec 2015 --> Dec 2017 Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Sep 2015 | Trial primary completion date: Mar 2021 --> Sep 2021
- | Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date: Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer (clinicaltrials.gov) - Aug 26, 2015
P2, N=42, Completed, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Sep 2015 | Trial primary completion date: Mar 2021 --> Sep 2021 Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014
- goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Trial completion: Bipolar Androgen-based Therapy for Prostate Cancer (BAT) (clinicaltrials.gov) - Aug 25, 2015
P2, N=33, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014 Active, not recruiting --> Completed
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: BOOSTER: Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer (clinicaltrials.gov) - Aug 21, 2015
P2, N=160, Recruiting, Sponsor: Japan Breast Cancer Research Group
Active, not recruiting --> Completed Trial primary completion date: Mar 2017 --> Jun 2017
- |||| opigolix (ASP1707) / Astellas
Trial completion: A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain (clinicaltrials.gov) - Aug 13, 2015
P2, N=912, Completed, Sponsor: Astellas Pharma Europe B.V.
Trial primary completion date: Mar 2017 --> Jun 2017 Active, not recruiting --> Completed
- ||||||| somatropin / Generic mfg.
Trial completion, Combination therapy: Phoenix: Somatropin + Leuprorelin vs Somatropin Alone in Pubertal Children With Idiopathic Short Stature (clinicaltrials.gov) - Aug 13, 2015
P3, N=94, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | leuprolide acetate for depot suspension / Generic mfg., flutamide / Generic mfg.
Phase classification, Metastases: Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c (clinicaltrials.gov) - Aug 12, 2015
P2, N=341, Completed, Sponsor: Takeda
Active, not recruiting --> Completed Phase classification: P2/3 --> P2
- leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg., bicalutamide / Generic mfg.
Trial completion, Monotherapy, Metastases: Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer (clinicaltrials.gov) - Aug 12, 2015
P1, N=30, Completed, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Phase classification: P2/3 --> P2 Recruiting --> Completed
- Xtandi (enzalutamide) / Pfizer, Astellas, Erleada (apalutamide) / J&J
Enrollment open: Micro RNAs to Predict Response to Androgen Deprivation Therapy (clinicaltrials.gov) - Aug 6, 2015
P=N/A, N=60, Recruiting, Sponsor: Medical College of Wisconsin
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
New P2 trial: Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer (clinicaltrials.gov) - Jul 27, 2015
P2, N=53, Not yet recruiting, Sponsor: University of California, San Francisco
- leuprolide acetate for depot suspension / Generic mfg.
Enrollment closed, Trial initiation date: Down-regulated Hormonally Controlled Cycles for Vitrification-warmed Blastocyst Transfers (clinicaltrials.gov) - Jul 22, 2015
P=N/A, N=300, Active, not recruiting, Sponsor: Antalya IVF
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting | Initiation date: Sep 2014 --> Dec 2014
- Yervoy (ipilimumab) / BMS
Trial primary completion date, IO biomarker: Neoadjuvant Ipilimumab in Prostate Cancer (clinicaltrials.gov) - Jul 6, 2015
P2a, N=20, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Active, not recruiting | Initiation date: Sep 2014 --> Dec 2014 Trial primary completion date: Sep 2015 --> Sep 2016
- |||| NN1213 / Novo Nordisk
Trial primary completion date: Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence (clinicaltrials.gov) - Jun 26, 2015
P3, N=496, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Jun 2016 --> Jun 2017
- Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial initiation date: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Jun 17, 2015
P2, N=56, Not yet recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Jun 2016 --> Jun 2017 Initiation date: Feb 2015 --> Nov 2015
- leuprolide acetate for depot suspension / Generic mfg.
Trial primary completion date: Effects of Estrogen Deficiency on Energy Expenditure (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=12, Recruiting, Sponsor: University of Colorado, Denver
Initiation date: Feb 2015 --> Nov 2015 Trial primary completion date: May 2015 --> May 2016
- | leuprolide acetate for depot suspension / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date: A Registry for Patients Treated on the Clinical Trial TAX 3503 (clinicaltrials.gov) - Jun 11, 2015
P3, N=19, Enrolling by invitation, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: May 2015 --> May 2016 Trial primary completion date: Mar 2015 --> Mar 2016
- || leuprolide acetate for depot suspension / Generic mfg.
Trial primary completion date: DUALTRIGGER: Study of Dual Trigger Ovulation in Oocyte Donors (clinicaltrials.gov) - Jun 11, 2015
P4, N=180, Recruiting, Sponsor: Weill Medical College of Cornell University
Trial primary completion date: Mar 2015 --> Mar 2016 Trial primary completion date: Jun 2014 --> Jun 2016
- docetaxel / Generic mfg.
Trial completion, Trial initiation date, Trial primary completion date: Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer (clinicaltrials.gov) - Jun 9, 2015
P2, N=40, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2014 --> Jun 2016 Active, not recruiting --> Completed | Initiation date: May 2008 --> May 2005 | Trial primary completion date: May 2016 --> Jun 2015
- leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
New P1 trial, Metastases: Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer (clinicaltrials.gov) - Jun 1, 2015
P1, N=50, Recruiting, Sponsor: Rutgers, The State University of New Jersey
- | Climara (estradiol) / Bausch Health, Bayer
Trial completion, Enrollment change: POWER: Prevention of Obesity in Women Via Estradiol Regulation (clinicaltrials.gov) - May 27, 2015
P3, N=150, Completed, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed | Initiation date: May 2008 --> May 2005 | Trial primary completion date: May 2016 --> Jun 2015 Recruiting --> Completed | N=300 --> 150
- Natrecor (nesiritide) / J&J
Enrollment change, Trial withdrawal: Testosterone Regulation of the Natriuretic Peptide System (clinicaltrials.gov) - May 6, 2015
P=N/A, N=0, Withdrawn, Sponsor: Massachusetts General Hospital
Recruiting --> Completed | N=300 --> 150 N=60 --> 0 | Not yet recruiting --> Withdrawn
- ||||| leuprolide acetate for depot suspension / Generic mfg.
New P4 trial: A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants (clinicaltrials.gov) - Apr 28, 2015
P4, N=300, Not yet recruiting, Sponsor: Takeda
- leuprolide acetate for depot suspension / Generic mfg.
Enrollment closed: Preservation of Ovarian Function After Hematopoietic Cell Transplant (clinicaltrials.gov) - Apr 25, 2015
P2, N=47, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
N=60 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- docetaxel / Generic mfg.
Trial primary completion date: Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer (clinicaltrials.gov) - Apr 14, 2015
P1/2, N=25, Active, not recruiting, Sponsor: University of Kansas
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Sep 2015
- ||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion: Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients" (clinicaltrials.gov) - Apr 3, 2015
P=N/A, N=2816, Completed, Sponsor: Takeda
Trial primary completion date: Mar 2015 --> Sep 2015 Active, not recruiting --> Completed
- progesterone / Generic mfg., leuprorelin depot / Generic mfg., estradiol valerate / Generic mfg.
Clinical: Endometrial Receptivity Profile in Patients With Endometrial Proliferation Defects (clinicaltrials.gov) - Apr 2, 2015
P=N/A, N=20, Enrolling by invitation, Sponsor: Reproductive Medicine Associates of New Jersey
- ||||| Suprefact (buserelin acetate) / Sanofi
Enrollment closed, Surgery: RTOG 0534: Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer (clinicaltrials.gov) - Apr 1, 2015
P3, N=1792, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- leuprolide acetate for depot suspension / Generic mfg.
Trial completion: Leuprolide in Treating Adults With Hypogonadotropism (clinicaltrials.gov) - Mar 25, 2015
P=N/A, N=45, Completed, Sponsor: University of Chicago
Recruiting --> Active, not recruiting Recruiting --> Completed
- leuprolide acetate for depot suspension / Generic mfg.
Trial completion, Trial initiation date: Leuprolide in Determining the Cause of Gonadotropin Deficiency (clinicaltrials.gov) - Mar 25, 2015
P=N/A, N=90, Completed, Sponsor: University of Chicago
Recruiting --> Completed Recruiting --> Completed | Initiation date: Dec 1999 --> Aug 1994
- |||| Firmagon (degarelix) / Astellas, Ferring
Enrollment open, Monotherapy: High-Dose Brachytherapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Mar 24, 2015
P1/2, N=163, Recruiting, Sponsor: Stanford University
Recruiting --> Completed | Initiation date: Dec 1999 --> Aug 1994 Not yet recruiting --> Recruiting
- Livial (tibolone) / Organon
New P4 trial: Psychological Impact of Amenorrhea in Women With Endometriosis (clinicaltrials.gov) - Mar 19, 2015
P4, N=50, Not yet recruiting, Sponsor: University of Cagliari
- Emcyt (estramustine) / Pfizer, Nippon Shinyaku
Trial primary completion date: Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Mar 2, 2015
P2, N=63, Active, not recruiting, Sponsor: University of Massachusetts, Worcester
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2015 --> Feb 2016
- ||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment closed: A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer (clinicaltrials.gov) - Feb 27, 2015
P2, N=125, Active, not recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Trial primary completion date: Feb 2015 --> Feb 2016 Recruiting --> Active, not recruiting
- Clinical: Micro RNAs to Predict Response to Androgen Deprivation Therapy (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=60, Not yet recruiting, Sponsor: Medical College of Wisconsin
- | Esmya (ulipristal acetate) / ASKA Pharma, Gedeon Richter, AbbVie, Perrigo Company
New P4 trial: Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma (clinicaltrials.gov) - Feb 12, 2015
P4, N=146, Recruiting, Sponsor: University Magna Graecia
- Esmya (ulipristal acetate) / ASKA Pharma, Gedeon Richter, AbbVie, Perrigo Company
New P4 trial: Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas (clinicaltrials.gov) - Feb 12, 2015
P4, N=42, Recruiting, Sponsor: University Magna Graecia
- ||| letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg.
Enrollment closed: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) (clinicaltrials.gov) - Feb 12, 2015
P2, N=84, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Esmya (ulipristal acetate) / ASKA Pharma, Gedeon Richter, AbbVie, Perrigo Company
New P4 trial: Ulipristal Acetate Versus GnRH Analogue and Myometrial Preservation (clinicaltrials.gov) - Feb 6, 2015
P4, N=110, Recruiting, Sponsor: University Magna Graecia